Work package 5: Phase II/IIb clinical trial in Burkina Faso and Zambia
Led by Groupe de Recherche Action en Santé, Burkina Faso
To continue clinical development of ShigOraVax up to determination of efficacy in children 12-59 months of age in a phase IIb study.
To determine the safety and immunogenicity of multiple formulations of ShigOraVax in participants 10-17 years, 5-9 years and 12-59 months of age, given as three doses four weeks apart.
To determine the efficacy of ShigOraVax in healthy children 12-59 months of age, given as three doses four weeks apart.